Creo Medical Group PLC (AIM:CREO) is discussed by Proactive research analyst Daniel Appiah who talks Thomas Warner through his latest report.
Two licensing revenue deals this year will see Creo’s technology used in robotics-assisted laparoscopic (keyhole) surgery to enhance the effectiveness of procedures.
Creo's technology allows minimally invasive endoscopic technology and licensing can be a very important revenue stream in future, Appiah adds. #proactiveinvestors #creomedical